Skip to main content

Peer Review reports

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Original Submission
20 Jul 2016 Submitted Original manuscript
24 Oct 2016 Author responded Author comments - Fei-Xiang Wu
24 Aug 2016 Reviewed Reviewer Report - JIN LI
25 Aug 2016 Reviewed Reviewer Report - Zhanwei Wang
18 Aug 2016 Reviewed Reviewer Report - David Darcy
Resubmission - Version 2
24 Oct 2016 Submitted Manuscript version 2
15 Feb 2017 Author responded Author comments - Fei-Xiang Wu
Resubmission - Version 3
15 Feb 2017 Submitted Manuscript version 3
8 Mar 2017 Author responded Author comments - Fei-Xiang Wu
Resubmission - Version 4
8 Mar 2017 Submitted Manuscript version 4
6 Apr 2017 Author responded Author comments - Fei-Xiang Wu
Resubmission - Version 5
6 Apr 2017 Submitted Manuscript version 5
18 Apr 2017 Author responded Author comments - Fei-Xiang Wu
Resubmission - Version 6
18 Apr 2017 Submitted Manuscript version 6
31 May 2017 Author responded Author comments - Fei-Xiang Wu
Resubmission - Version 7
31 May 2017 Submitted Manuscript version 7
6 Jul 2017 Author responded Author comments - Fei-Xiang Wu
Resubmission - Version 8
6 Jul 2017 Submitted Manuscript version 8
11 Aug 2017 Author responded Author comments - Fei-Xiang Wu
Resubmission - Version 9
11 Aug 2017 Submitted Manuscript version 9
Publishing
14 Aug 2017 Editorially accepted
12 Sep 2017 Article published 10.1186/s12885-017-3545-5

You can find further information about peer review here.

Back to article page